RxDoctor Payments DataLook up a doctor →

Fahd Al-Saghir, MD

Nephrology · Pontiac, MINPI 1073584223

Payments from drug & device makers

$3,856,482in general payments, 2019–2025

Across 656 payments — averaging $5878.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$3M
  • Eli Lilly$231K
  • GSK$181K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$150K
  • AstraZeneca$131K
  • Akebia Therapeutics Inc$125K
  • plus $36K from 32 others
$88,967in research payments, 2019–2025

Across 1 payment — averaging $88,967 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$89K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,856,482 in reported general payments places this provider in the 95th percentile of 325 nephrology providers in Michigan.

See all nephrology providers in Michigan

Medicare billing

Part B allowed, 2024
$424,443
Medicare patients
425
Services billed
4,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in Pontiac

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →